

300436

2021015

2020

--	--	--	--

 ✓

✓

140,000,000 10 0

0 10 0

 ✓

1

				300436
	89		89	
	B 10 B		B 10 B	
	0591-38305305		0591-38305305	
	0591-38305333		0591-38305333	
	niuniu@cosunter.com		wangq@cosunter.com	

2

“ . ”

1
1.1
1

2020

1

25

2019 9

2019 12

2020

2020 4

421.19%

99.15%



(FGD) 福甘定[®]
富马酸替诺福韦



(FGD) 恩甘定[®]
恩替卡韦胶囊



(AGO) 阿甘定[®]
阿德福韦酯片



(AGO) 阿甘定[®]
拉米夫定片

2

2020

“ ”

“ ” “ ”

10,000

“ ”



1.2

1

TAF

“ ” TAF TAF 25mg
TAF 300mg TDF
2019 11 TAF TAF
TAF 2020 12 15
2
sofosbuvir 1 2017 9 34494
36170 2018
2019 8
2020 12 14
3
(ED) 2019 7
2020 10 15
4 2021 3 25
ED (ED) (BPH)
2020 8
2
2015 IPO
1
GST-HG161 c-Met
c-Met
GST-HG161 c-MET 2019 7 9 I c-Met
c-Met GST-HG161 900mg
GST-HG161 Ib/II
GST-HG161 PCT 15
2
GST-HG151
2019 4 GST-HG151 NASH
GST-HG151 PCT 12
3
2015 “ ” GST-HG131/GST-HG121 GST-HG141
2017 AASLD
EASL
GST-HG141 HBVcccDNA cccDNA GST-HG141
2019 11
Ia I I Ib CRO PI
PCT GST-HG141
14

GST-HG131 First-in-Class
 HBV-RNA HBsAg GST-HG131 2020 3
 Ia HBsAg GST-HG131 PCT I PI

GST-HG121 RNA HBsAg
 2020 9 GST-HG121 2020 6 PCT

创新药名称	临床前	临床申请	I期临床	II期临床	III期临床	生产注册申请
新型肝癌靶向药物GST-HG161	→					
非酒精性脂肪肝病及肝纤维化可逆转创新药GST-HG151	→					
乙肝核心蛋白抑制剂GST-HG141	→					
乙肝表面抗原抑制剂GST-HG131	→					
乙肝表面抗原抑制剂GST-HG121	→					

GST-HG161 GST-HG141 GST-HG131

III

1
2

“ ”

3

2019 9

25

2020 4

2019 12

2020 1

1

(IQVIA)
5%

2017 1.1
1.5

2018 1.2

2023

(IQVIA)

2018

1,370

2008

240%

2023

1,400-1,700

2

2015

3.9%

62.6%

1

HBV

2017

2015

2.57

6.2%

1.15

2015

88.7

9%

8%

170

2019

2,000

3,000

2018

5%

6%

7,000

19%

11%

280

2015

170

2017

2016

80%

2

HCV

2015

7100

HCV
HCV
2019

39.9
560

HCV
16.0153/10

HCV

2019

1,000

1

2017 9

3

NAFLD

NASH
>25

NAFLD
NAFLD
NAFLD

6.3

45

MetS

10

30

NAFLD

NASH

NASH

NAFLD

NAFLD
NAFLD

Discovery

NASH

NAFLD NASH
2025

Nature Reviews Drug
150

4

2018

9

26.67/10

23.31/10

36.5

31.9

(HCC)

5

drug-induced liver in jury DILI
TCM-NM-HP-DS

/

ADR

NSAIDs

1100

DILI

TCM-NM-HP-DS

DILI DILI 23.80/10 DILI DILI
 3 20%

4

3

1

□ √

	2020	2019		2018
	368,489,433.97	414,866,330.97	-11.18%	402,400,221.06
	14,824,518.08	10,741,879.19	38.01%	16,484,410.89
	1,470,888.36	-3,534,179.57	141.62%	8,526,446.56
	15,597,456.96	33,988,140.40	-54.11%	10,943,959.05
/	0.1059	0.0767	38.07%	0.12
/	0.1056	0.0767	37.68%	0.12
	2.60%	2.08%	0.52%	3.17%
	2020	2019		2018
	1,005,780,979.42	895,878,350.99	12.27%	854,519,609.79
	576,597,504.24	565,575,598.98	1.95%	553,879,649.25

2



4

1

10


	16,037		14,992	0	0
10					
		15.98%	22,368,651	0	3,000,000
		9.72%	13,614,866	10,211,149	10,000,000
		9.67%	13,536,700	10,152,525	
		7.23%	10,125,000	0	
		5.36%	7,500,000	5,625,000	
E1	19	5.14%	7,200,000	0	
E2	19	3.93%	5,500,000	0	
		0.86%	1,210,000	0	
		0.72%	1,010,000	0	
		0.62%	870,000	0	
		1	19 E1 2019	2	19 E2

2

10

□ √

3



5

1

2020

1482.45

38.01%

3.68

11.18%

1

OTC

2021 3 25

1

4

Dr. John Mao

FACO

CSCO

GST-HG161 I 900mg

Ia Ib

PI Ib/II

CRO

GST-HG121 2020 8

50 PCT

2

BD

OTC

OTC

99.15%

421.19%

1.62
5% 4.06% 92.5%

3
2020 3

55,000.00 A 2,800 2,800

2020 10 30

4

Wei-Zhong Mao OTC John

280.00 2020 2020 5 12 35

5

2021 1 6 2021

6

3,700

2

√

3 10%

√

	205,076,138.93	123,576,565.98	60.26%	-20.57%	-41.01%	-20.88%
	137,203,809.89	109,530,279.06	79.83%	5.15%	5.79%	0.48%

4

√

5

√

1 - -

421.19% 99.15%

2

6

□ √

7

1

√ □
 2017 7 5 14 — 2017 [2017]22
 2020 1 1
 2020 1 1 2017 14 -
 2020 1 1

2

□ √

3

□ √